halofuginone has been researched along with Bilateral Wilms Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fridman, E; Genina, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y | 1 |
| Genin, O; Iluz, M; Kawada, N; Leon, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y; Yoshizato, K | 1 |
2 other study(ies) available for halofuginone and Bilateral Wilms Tumor
| Article | Year |
|---|---|
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Child, Preschool; Collagen; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Injections, Intraperitoneal; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones; Receptor, ErbB-2; Transplantation, Heterologous; Wilms Tumor; WT1 Proteins | 2005 |
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Synergism; Fibroblasts; Humans; Male; Mice; Mice, Nude; Muscles; Myoblasts; Piperidines; Prostatic Neoplasms; Quinazolinones; Taxoids; Tumor Cells, Cultured; Wilms Tumor | 2007 |